Premium
Effect of oral verapamil on glibenclamide stimulated insulin secretion.
Author(s) -
Semple CG,
Omile C.,
Buchanan KD,
Beastall GH,
Paterson KR
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb05248.x
Subject(s) - glibenclamide , verapamil , medicine , endocrinology , insulin , crossover study , placebo , oral administration , glucagon , antagonist , pharmacology , diabetes mellitus , calcium , receptor , alternative medicine , pathology
In order to study the effect of the calcium antagonist, verapamil, on glibenclamide stimulated insulin release, nine healthy fasted male volunteers were given 5 mg oral glibenclamide with either 120 mg oral verapamil or placebo in a double‐blind crossover manner 1 week apart. Blood was withdrawn at intervals for drug, hormonal and glucose estimations. Concomitant administration of verapamil resulted in higher levels of glibenclamide at each time point (P less than 0.01) suggesting that verapamil interferes with glibenclamide metabolism. However, levels of plasma glucose, C‐peptide, insulin and glucagon did not differ between the verapamil and placebo studies.